Progress in Ebola Virus Vaccine Development
نویسندگان
چکیده
منابع مشابه
Progress of vaccine and drug development for Ebola preparedness
Since the first case of Ebola virus disease (EVD) in Guinea was reported in March 2014 by World Health Organization (WHO), the outbreak has continued through the year and the total number of 19,065 patients was reported as the confirmed or suspected in the EVD-affected countries. Among the cases, 7,388 patients were reported death by 19 December. Currently, available therapeutics to treat the i...
متن کاملResearch Progress on Ebola Hemorrhagic Fever Vaccine
Ebola hemorrhagic fever is a potent infectious disease by Ebola virus caused 90% mortality rate. Ebola virus was first isolated in 1976 by, for single-stranded negative segment, non-segmented, enveloped RNA viruses belonging to filamentous virus family. Ebola virus can be divided into five different subtypes. Vaccination is the most conventional and effective prevention and infection control me...
متن کاملRespiratory Syncytial Virus: Current Progress in Vaccine Development
Respiratory syncytial virus (RSV) is the etiological agent for a serious lower respiratory tract disease responsible for close to 200,000 annual deaths worldwide. The first infection is generally most severe, while re-infections usually associate with a milder disease. This observation and the finding that re-infection risks are inversely associated with neutralizing antibody titers suggest th...
متن کاملProgress in HIV vaccine development.
Recent advances in HIV vaccine development include initiation of the first efficacy trials and substantial expansion of the preclinical pipeline. Several preclinical candidate vaccines have induced strong cellular immune responses and provided impressive protection against AIDS in non-human primate models; however, candidates that induce broadly neutralizing antibodies remain elusive.
متن کاملHepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of Infectious Diseases
سال: 2017
ISSN: 0022-1899,1537-6613
DOI: 10.1093/infdis/jix190